☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - December 2023

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2023. This month there are three guidelines, two technology evaluations and two technology appraisals that impact upon primary care.

The Acne vulgaris: management guideline has been updated. It covers management of acne vulgaris in primary and specialist care. The update clarifies recommendations on oral isotretinoin treatment in line with the 2023 MHRA advice on the introduction of new safety measures.

The Digitally enabled therapies for adults with depression health technology assessment has been updated. Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. This update provide further information in the evidence generation plan.

The Digitally enabled therapies for adults with anxiety disorders health technology assessment has been updated. Six digitally enabled therapies can be used as treatment options for adults with anxiety disorders while further evidence is generated on their clinical and cost effectiveness. This update provide further information in the evidence generation plan.

The Cardiovascular disease: risk assessment and reduction, including lipid modification guideline has been published. It covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD and lifestyle changes and lipid-lowering treatment for primary and secondary prevention of CVD. It replaces previous guidance and contains a new recommendation on the target lipid level for secondary prevention of CVD.

The Empagliflozin for treating chronic kidney disease technology appraisal has been published. This treatment is recommended as an option for treating chronic kidney disease (CKD) in adults, only if:

  • it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
  • people have an estimated glomerular filtration rate of:
    • 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or
    • 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2 and either:
      • a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or
      • type 2 diabetes.

The Targeted-release budesonide for treating primary IgA nephropathy technology appraisal has been published. This treatment is recommended as an option for treating primary immunoglobulin A nephropathy. This recommendation is contingent on a commercial agreement and as such it is expected prescribing would remain with a specialist.

The Bipolar disorder: assessment and management guideline has been updated. It covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. This update amends recommendations in line with the latest MHRA guidance on the use of valproate.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - December 2023' by emailShare 'NICE Guidance - December 2023' on FacebookShare 'NICE Guidance - December 2023' on TwitterShare 'NICE Guidance - December 2023' on MastodonShare 'NICE Guidance - December 2023' on LinkedInShare 'NICE Guidance - December 2023' on reddit

Antiviral Medicines Authorised for Influenza Season 2023/24

The Chief Medical Officer has written to healthcare professionals via the Central Alerting System (PDF) to advise that antiviral medicines may now be prescribed at NHS expense due to rising levels in reporting of influenza-like illness.

UKHSA surveillance data indicates that influenza is circulating in the community and as such GPs and other prescribers working in primary care may now prescribe antiviral medicines for the prophylaxis and treatment of influenza. NICE has issued guidance on the treatment and prevention of influenza with antiviral medication and the UKHSA has also published guidance on how to manage influenza using anti-viral agents.

Clinicians should remember to endorse the prescription with 'SLS' to ensure that it can be dispensed in community pharmacies without undue delay.

Action: Clinicians should be aware of this letter and familiarise themselves with the current prescribing guidance.

Share 'Antiviral Medicines Authorised for Influenza Season 2023/24' by emailShare 'Antiviral Medicines Authorised for Influenza Season 2023/24' on FacebookShare 'Antiviral Medicines Authorised for Influenza Season 2023/24' on TwitterShare 'Antiviral Medicines Authorised for Influenza Season 2023/24' on MastodonShare 'Antiviral Medicines Authorised for Influenza Season 2023/24' on LinkedInShare 'Antiviral Medicines Authorised for Influenza Season 2023/24' on reddit

Drug Safety Update - December 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for December 2023 (PDF).

This issue reminds clinicians of the risk of pathological gambling and other impulse control disorders associated with aripiprazole use. This reminder has been issued due to a rise in Yellow Card reports. Clinicians should ensure patients and their caregivers are aware to be alert to the development of new or increased urges to gamble and other impulse control symptoms, such as excessive eating or spending, or an abnormally high sex drive. In such cases, dose reductions or medication cessation may be required.

This issue also warns clinicians to be aware of the risk of cobalt sensitivity reactions seen in association with vitamin B12 (hydroxocobalamin and cyanocobalamin) treatments. The case reports have typically described skin reactions occurring within 72 hours of starting treatment. When such reactions arise, the risks and benefits of continued treatment should be reassessed. Treatment can be continued with appropriate advice and management of the reaction symptoms. Individuals with a known cobalt allergy should speak to a healthcare professional before starting B12 treatments.

Lastly in this issue is a summary of letters to healthcare professionals in November. These generally related to supply issues and recalls but also a reminder that as from January 2024 valproate containing medicines must not be started in new patients (male or female) younger than 55 years, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or unless there are compelling reasons that the reproductive risks do not apply.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - December 2023' by emailShare 'Drug Safety Update - December 2023' on FacebookShare 'Drug Safety Update - December 2023' on TwitterShare 'Drug Safety Update - December 2023' on MastodonShare 'Drug Safety Update - December 2023' on LinkedInShare 'Drug Safety Update - December 2023' on reddit

SMC Update - December 2023

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Osilodrostat (Isturisa®) has been rejected for use in the treatment of endogenous Cushing’s syndrome in adults. The manufacturer failed to make a submission for this indication. In considering the product license, it would be expected that this medicine would be prescribed and monitored by a specialist.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - December 2023' by emailShare 'SMC Update - December 2023' on FacebookShare 'SMC Update - December 2023' on TwitterShare 'SMC Update - December 2023' on MastodonShare 'SMC Update - December 2023' on LinkedInShare 'SMC Update - December 2023' on reddit

CKS Updates - November 2023

During November 2023 Clinical Knowledge Summaries were published or updated in the following areas.

The topics have all been reviewed and updated with minor structural and layout changes. The management section in the Allergic rhinitis topic has been updated in line with current literature and information on risk factors and on nasal sprays has been added. The Neck pain - cervical radiculopathy topic has been updated to include short sections detailing risk factors and complications which can arise due to cervical radiculopathy.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - November 2023' by emailShare 'CKS Updates - November 2023' on FacebookShare 'CKS Updates - November 2023' on TwitterShare 'CKS Updates - November 2023' on MastodonShare 'CKS Updates - November 2023' on LinkedInShare 'CKS Updates - November 2023' on reddit

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.